Lipocine announces late breaking oral presentation of data from the phase 2 study of lpcn 1148 at easl congress 2024

Salt lake city , may 8, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company, today announced that data from the phase 2 study of lpcn 1148 has been selected for a late breaking oral presentation at the european association for the study of liver ("easl") congress, to take place june 5 to 8, 2024 in milan, italy. presentation details title    intervention with oral lpcn 1148 improves sarcopenia and hepatic encephalopathy ("he") in patients with cirrhosis: a 52-week phase 2 randomized clinical trial presenter:   dr. arun j.
LPCN Ratings Summary
LPCN Quant Ranking